The Incredible Adventure of Omalizumab
International Journal of Molecular Sciences · 06.03.2024 · 25 (5) · 3056
DOI: 10.3390/ijms25053056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.03.2024. Verfasst von Christian Domingo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma…. Hauptthemen laut MEDLINE: Asthma, Hypersensitivity. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The basis of our current understanding of allergies begins with the discovery of IgE in the mid-1960s. The whole theory of the physiology and pathophysiology of allergic diseases, including rhinitis and asthma, dates from that period. Among the key regions of IgE identified were the FAB (fragment antigen binding) portion that has the ability to capture allergens, and the Cε3 domain, through which IgE binds to its membrane receptor. It was then postulated that blocking IgE at the level of the Cε3 domain would prevent it from binding to its receptor and thus set in motion the allergic cascade. This was the beginning of the development of omalizumab, a monoclonal antibody with an anti-IgE effect. In this article, we review the pathophysiology of allergic disease and trace the clinical development of omalizumab. We also review the benefits of omalizumab treatment that are apparently unrelated to allergies, such as its effect on immunity and bronchial remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08202 Sabadell, Spain.
- Unitat d'Anatomia, Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona (UAB), 08193 Cerdanyola, Spain.
ORCID-Profile: Christian Domingo, Daniel R Monserrate, Rosa M Mirapeix
Zitieren
APA
Domingo, C., Monserrate, D. R., Sogo, A., & Mirapeix, R. M. (2024). The Incredible Adventure of Omalizumab. International Journal of Molecular Sciences, 25(5), 3056. https://doi.org/10.3390/ijms25053056
Vancouver
Domingo C, Monserrate DR, Sogo A, Mirapeix RM. The Incredible Adventure of Omalizumab. International Journal of Molecular Sciences. 2024;25(5):3056. doi:10.3390/ijms25053056
BibTeX
@article{Domingo2024,
author = {Domingo, Christian and Monserrate, Daniel R and Sogo, Ana and Mirapeix, Rosa M},
title = {The Incredible Adventure of Omalizumab},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {5},
pages = {3056},
doi = {10.3390/ijms25053056}
}
EUVIMED